Wed, 07th Sep 2016 08:09
(ShareCast News) - Inhaled airways disease focused pharmaceuticals company Vectura Group confirmed an announcement from its alliance partner Novartis on Monday, that new analyses from the head-to-head FLAME study confirmed that Ultibro Breezhaler is a "more effective option" for patients at risk of
Read more(ShareCast News) - Novartis has published data about a respiratory drug combination delivered using an inhaler designed in collaboration with Vectura that shows patients are twice as likely to persist with treatment over 12 months than with a popular product already on the market. Patients using Nov
Read more(ShareCast News) - Investec resumed coverage on Vectura at 'buy' with a 200p price target following completion of the SkyePharma deal. "In our view, the benefits from a broader royalty base, improved cash flows, as well as an enhanced competency set, are yet to be fully reflected in the share price,
Read more(ShareCast News) - Inhaled airways disease focused company Vectura Group announced on Friday that a sales milestone receipt of $8m has been triggered following confirmation by Pacira Pharmaceuticals that worldwide annual net sales of EXPAREL, on a cash received basis to 30 June, were above $250m. Th
Read more* Digitally connected devices aim to track medicine use * GSK, AstraZeneca, Novartis all working on smart inhalers * Innovation drive comes as sector faces growing competition By Ben Hirschler LONDON, July 20 (Reuters) - Makers of inhalers to treat asthma and chronic lung
Read more(ShareCast News) - Skyepharma's chief financial officer Andrew Derodra has pocketed a healthy cash injection after the completion of the merger with Vectura. Derodra exercised nil-cost options over 150,000 Skyepharma shares that were a bonus in his long-term incentive plan that vested on completion
Read more